Prevention of Q fever endocarditis

The Lancet Infectious Diseases

Volumn 11, Issue 2, 2011, Pages 82-83

  Limonard, Gijs J M ^a   Nabuurs Franssen, Marrigje H ^a   Dekhuijzen, P N Richard ^a   Groot, Cornelis A R ^a  

^a DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; DEVELOPING COUNTRY; DISEASE COURSE; ECHOCARDIOGRAPHY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; PROSPECTIVE STUDY; Q FEVER; Q FEVER ENDOCARDITIS; RHEUMATIC FEVER; RISK FACTOR; SEROLOGY; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; Q FEVER; RISK ASSESSMENT;

EID: 78751698196     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70016-0     Document Type: Letter

References (5)

1. Million M, Thuny F, Richet H, Raoult D Long-term outcome of Q fever endocarditis: a 26-year personal survey. Lancet Infect Dis 2010, 10:527-535.
2. Landais C, Fenollar F, Thuny F, Raoult D From acute Q fever to endocarditis: serological follow-up strategy. Clin Infect Dis 2007, 44:1337-1340.
3. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 2001, 33:312-316.
4. Tissot-Dupont H, Vaillant V, Rey S, Raoult D Role of sex, age, previous valve lesion, and pregnancy in the clinical expression and outcome of Q fever after a large outbreak. Clin Infect Dis 2007, 44:232-237.
5. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999, 83:897-902.